TORONTO--(BUSINESS WIRE)--Dec. 21, 2005--Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today the submission of a Citizen Petition with the Food and Drug Administration (FDA) to require rigorous bioequivalence testing for generic products that reference Wellbutrin XL(R) before they can be approved. Biovail has taken this step to protect patients against potentially serious risks (particularly seizures) which are currently disclosed in the approved Wellbutrin XL(R) labeling, and to ensure that generic versions of Wellbutrin XL(R) are as safe and effective as the innovator product.
